FUN
Six Flags Entertainment Corporation
stock NYSE

$IOVA
$IOVA — 21% SHORT. FDA-APPROVED. AND THE BIG CATALYST HASN'T EVEN HIT YET.
Alright degenerates, here’s one worth putting on the radar.
87.1 MILLION shares of IOVA are currently sold short.
That’s 20.9% of the float with roughly 7.4 days to cover.
Normally I’d assume the shorts know something.
Problem is… this isn’t some pre-revenue biotech surviving on PowerPoints and hopes.
IOVA already has an FDA-approved cancer treatment and just did $99.3M in quarterly revenue, +66% YoY.
THE ACTUAL BUSINESS
Amtagvi is the first FDA-approved TIL therapy and is already commercially treating advanced melanoma.
Q2:
\- $99.3M revenue
\- 56% gross margin
\- \~$304M cash
\- runway into 2H 2028
\- 95+ treatment centers
\- fully owned manufacturing
\- no note payable on the June balance sheet
And Iovance controls the global TIL platform.
NOW THE FUN PART: LUNG CANCER
The upcoming IOV-LUN-202 update could completely change how this company is valued.
Existing data showed:
25.6% response rate
Median response duration not reached after 25.4 months
Standard-of-care docetaxel benchmark: 12.8% response rate.
Iovance estimates the commercial opportunity in this lung setting at roughly 7X its current melanoma opportunity.
Management recently described the lung program as “very positive”, urged investors to watch it carefully and suggested there could be more coming than investors expect.
👀
AND LUNG ISN’T THE ONLY SHOT
Sarcoma: early 50% response rate, FDA Fast Track.
Frontline melanoma: Phase 3 combining lifileucel + Keytruda.
Endometrial cancer: active clinical program.
Then you have next-gen TIL:
PD-1 knockout TIL
IL-12 tethered TIL
next-gen IL-2
Being explored across lung, melanoma, colorectal, breast, head & neck and more.
THEN THERE’S WAYNE ROTHBAUM
Largest shareholder. 30M shares.
He co-founded Acerta Pharma and later sold it to AstraZeneca.
Board member Athena Countouriotis ran Turning Point Therapeutics until Bristol Myers Squibb acquired it.
Chairman Iain Dukes previously ran Business Development & Licensing at Merck Research Laboratories.
Interesting collection of people for a company with an approved drug, proprietary manufacturing, global rights and a pipeline expanding across solid tumors.
Does that mean buyout? No. Pure speculation.
But it’s worth noticing.
Oh, and Iovance says it has 400+ granted/allowed patents and 1,000+ additional patent applications, with expected protection into 2042+.
THE SETUP
Real product ✅
Real revenue ✅
Huge lung catalyst ✅
Multiple additional indications ✅
Experienced biotech dealmakers ✅
20.9% SHORT ✅
Clinical data can absolutely wreck this thesis. This is biotech.
But if lung delivers?
87 million short shares suddenly become a very interesting number.
I’m long.

I miss the time when I use to come to wsb and actually find what’s the news FUCK THE MODS THEY TOOK ALL FUN OUT BY MAKING LIVE CHAT NOW ITS ALL SPAMS

$IOVA
$IOVA — 21% SHORT. FDA-APPROVED. AND THE BIG CATALYST HASN'T EVEN HIT YET.
Alright degenerates, here’s one worth putting on the radar.
87.1 MILLION shares of IOVA are currently sold short.
That’s 20.9% of the float with roughly 7.4 days to cover.
Normally I’d assume the shorts know something.
Problem is… this isn’t some pre-revenue biotech surviving on PowerPoints and hopes.
IOVA already has an FDA-approved cancer treatment and just did $99.3M in quarterly revenue, +66% YoY.
THE ACTUAL BUSINESS
Amtagvi is the first FDA-approved TIL therapy and is already commercially treating advanced melanoma.
Q2:
\- $99.3M revenue
\- 56% gross margin
\- \~$304M cash
\- runway into 2H 2028
\- 95+ treatment centers
\- fully owned manufacturing
\- no note payable on the June balance sheet
And Iovance controls the global TIL platform.
NOW THE FUN PART: LUNG CANCER
The upcoming IOV-LUN-202 update could completely change how this company is valued.
Existing data showed:
25.6% response rate
Median response duration not reached after 25.4 months
Standard-of-care docetaxel benchmark: 12.8% response rate.
Iovance estimates the commercial opportunity in this lung setting at roughly 7X its current melanoma opportunity.
Management recently described the lung program as “very positive”, urged investors to watch it carefully and suggested there could be more coming than investors expect.
👀
AND LUNG ISN’T THE ONLY SHOT
Sarcoma: early 50% response rate, FDA Fast Track.
Frontline melanoma: Phase 3 combining lifileucel + Keytruda.
Endometrial cancer: active clinical program.
Then you have next-gen TIL:
PD-1 knockout TIL
IL-12 tethered TIL
next-gen IL-2
Being explored across lung, melanoma, colorectal, breast, head & neck and more.
THEN THERE’S WAYNE ROTHBAUM
Largest shareholder. 30M shares.
He co-founded Acerta Pharma and later sold it to AstraZeneca.
Board member Athena Countouriotis ran Turning Point Therapeutics until Bristol Myers Squibb acquired it.
Chairman Iain Dukes previously ran Business Development & Licensing at Merck Research Laboratories.
Interesting collection of people for a company with an approved drug, proprietary manufacturing, global rights and a pipeline expanding across solid tumors.
Does that mean buyout? No. Pure speculation.
But it’s worth noticing.
Oh, and Iovance says it has 400+ granted/allowed patents and 1,000+ additional patent applications, with expected protection into 2042+.
THE SETUP
Real product ✅
Real revenue ✅
Huge lung catalyst ✅
Multiple additional indications ✅
Experienced biotech dealmakers ✅
20.9% SHORT ✅
Clinical data can absolutely wreck this thesis. This is biotech.
But if lung delivers?
87 million short shares suddenly become a very interesting number.
I’m long.

I miss the time when I use to come to wsb and actually find what’s the news FUCK THE MODS THEY TOOK ALL FUN OUT BY MAKING LIVE CHAT NOW ITS ALL SPAMS

spy last 20 minute puts are SO FUN 😹😹😹 scalped $500 last 15 minutes

Cat? CEO? Small SHF getting blowed up?
Who knows, but it's FUN!

You don’t think skinny people would be more active and do more things with their kids? 40% of Americans are obese and can’t walk around parks that are hundreds of acres large without real difficulty. Once you’re below a 30bmi it’s much easier, 27.5 you feel ten years younger again. Foot traffic was up last year and we can’t say it’s because the middle class is thriving. 
My wife and I are anecdotal evidence for my DD. All four of our kids have season passes and FUN will collect thousands from us. It’s a fairly cheap good time and the cost of all the glp’s keep coming down. You can take a pill now for a couple hundred bucks per month. 

These glp 1 type drugs are just getting started and all these types of companies should be avoided. They’re also up against stiff competition from multiple competitors that aren’t exactly doing great either. I was trading Dutch bros before walking away from this segment of the Mkt including all food companies. 
The real question is what are these formerly obese people going to do besides eat away their money now? I’m long Lilly and bought a little six flags for FUN, that’s the awful ticker. I think there’s a chance they’ll continue to gain more foot traffic from people getting thinner and it’s a very small bet.